Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care.

CommNETs NETs QPIs cancer care modified Delphi neuroendocrine tumour quality performance indicators

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
12 Sep 2019
Historique:
received: 31 07 2019
revised: 05 09 2019
accepted: 07 09 2019
entrez: 25 9 2019
pubmed: 25 9 2019
medline: 25 9 2019
Statut: epublish

Résumé

Quality performance indicators (QPIs) are used to monitor the delivery of cancer care. Neuroendocrine tumours (NETs) are a family of individually uncommon cancers that derive from neuroendocrine cells or their precursors, and can occur in most organs. There are currently no QPIs available for NETs and their heterogeneity makes QPI development difficult. CommNETs is a collaboration between NET clinicians, researchers and advocates in Canada, Australia and New Zealand. We created QPIs for NETs using a three-step consensus process. First, a multidisciplinary team used the nominal group technique to create candidates (

Identifiants

pubmed: 31547431
pii: jcm8091455
doi: 10.3390/jcm8091455
pmc: PMC6780732
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Ministry of Health, New Zealand
ID : 362574/00 NET Tumour Standards QPI Development

Références

Can J Surg. 2005 Dec;48(6):441-52
pubmed: 16417050
Pancreas. 2017 Jul;46(6):715-731
pubmed: 28609357
J Clin Oncol. 2008 Jun 20;26(18):3063-72
pubmed: 18565894
Curr Oncol. 2018 Oct;25(5):e356-e364
pubmed: 30464685
Neuroendocrinology. 2017 Feb 11;105(3):196-200
pubmed: 28190015
J Oncol Pract. 2019 Jul;15(7):e636-e643
pubmed: 31150310
Curr Oncol. 2016 Apr;23(2):81-90
pubmed: 27122972
World J Surg. 2007 May;31(5):1022-30
pubmed: 17429568
Cancer Manag Res. 2018 Nov 13;10:5629-5638
pubmed: 30519109
JAMA Oncol. 2017 Oct 1;3(10):1335-1342
pubmed: 28448665
Curr Oncol. 2013 Oct;20(5):e455-64
pubmed: 24155642
J Glob Oncol. 2016 Oct 12;3(4):380-388
pubmed: 28831446
Neuroendocrinology. 2016;103(2):172-85
pubmed: 26731013
JAMA Oncol. 2018 Nov 1;4(11):1597-1604
pubmed: 30054622
Eur J Cancer. 2017 Nov;86:59-81
pubmed: 28963914
Endocrinol Metab Clin North Am. 2011 Mar;40(1):1-18, vii
pubmed: 21349409
HPB (Oxford). 2019 Apr;21(4):444-455
pubmed: 30316625
J Gynecol Oncol. 2018 Nov;29(6):e83
pubmed: 30207093
Pancreas. 2013 May;42(4):557-77
pubmed: 23591432
Cancer. 2015 Feb 15;121(4):589-97
pubmed: 25312765
Neuroendocrinology. 2016;103(2):119-24
pubmed: 26784901
Pancreas. 2017 Jul;46(6):707-714
pubmed: 28609356
Asia Pac J Clin Oncol. 2015 Sep;11(3):262-71
pubmed: 25871458

Auteurs

Braden Woodhouse (B)

Discipline of Oncology, Faculty of Medicine and Health Sciences, The University of Auckland, Auckland 1023, New Zealand. b.woodhouse@auckland.ac.nz.

Sharon Pattison (S)

Department of Medicine, University of Otago, Dunedin 9016, New Zealand. sharon.pattison@otago.ac.nz.

Eva Segelov (E)

Department of Medical Oncology, Monash University and Monash Health, Melbourne 3800, Australia. eva.segelov@monash.edu.

Simron Singh (S)

Department of Medical Oncology, Sunnybrook Odette Cancer Center, University of Toronto, Toronto, ON M4N 3M5, Canada. simron.singh@sunnybrook.ca.

Kate Parker (K)

Discipline of Oncology, Faculty of Medicine and Health Sciences, The University of Auckland, Auckland 1023, New Zealand. kate.parker@auckland.ac.nz.

Grace Kong (G)

Department of Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne 3000, Australia. grace.kong@petermac.org.

William Macdonald (W)

Department of Nuclear Medicine, Fiona Stanley Hospital, Perth 6150, Australia. william.macdonald@health.wa.gov.au.

David Wyld (D)

Department of Medical Oncology, Royal Brisbane and Women's Hospital, Brisbane 4029, Australia. david.wyld@health.qld.gov.au.
School of Medicine, University of Queensland, Brisbane 4072, Australia. david.wyld@health.qld.gov.au.

Goswin Meyer-Rochow (G)

Department of General Surgery, Waikato Hospital, Hamilton 3204, New Zealand. win.meyer-rochow@waikatodhb.health.nz.

Nick Pavlakis (N)

Department of Medical Oncology, Royal North Shore Hospital, Sydney 2065, Australia. nick.pavlakis@sydney.edu.au.

Siobhan Conroy (S)

Unicorn Foundation New Zealand, Auckland, New Zealand. siobhan@unicornfoundation.org.nz.

Vallerie Gordon (V)

Department of Medical Oncology, Cancer Care Manitoba, Winnipeg, MB R3E 0V9, Canada. vgordon1@cancercare.mb.ca.

Jonathan Koea (J)

Department of General Surgery, North Shore Hospital, Auckland 0620, New Zealand. jonathan.koea@waitematadhb.govt.nz.

Nicole Kramer (N)

Department of Pathology, North Shore Hospital, Auckland 0620, New Zealand. nicole.kramer@waitematadhb.govt.nz.

Michael Michael (M)

Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne 3000, Australia. michael.michael@petermac.org.

Kate Wakelin (K)

Unicorn Foundation, Melbourne, Australia. kate.wakelin@unicornfoundation.org.au.

Tehmina Asif (T)

Department of Medical Oncology, Saskatchewan Cancer Agency, Saskatoon, SK S4W 0G3, Canada. tehmina.asif@saskcancer.ca.

Dorothy Lo (D)

Department of Medical Oncology, St Joseph's Health Care, Toronto, ON M6R 1B5, Canada. dlo@stjoestoronto.ca.

Timothy Price (T)

Department of Medical Oncology, The Queen Elizabeth Hospital, Adelaide 5011, Australia. timothy.price@health.sa.gov.au.

Ben Lawrence (B)

Discipline of Oncology, Faculty of Medicine and Health Sciences, The University of Auckland, Auckland 1023, New Zealand. b.lawrence@auckland.ac.nz.
Department of Medical Oncology, Auckland City Hospital, Auckland 1023, New Zealand. b.lawrence@auckland.ac.nz.

Classifications MeSH